Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
4.820
-0.020 (-0.41%)
Apr 29, 2026, 9:52 AM EDT - Market open
Niagen Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 17.38 | 8.55 | -4.94 | -16.54 | -27.13 | Upgrade
|
| Depreciation & Amortization | 0.79 | 1.48 | 1.71 | 1.88 | 1.63 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | -0.02 | -0.01 | 0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 0 | - | - | Upgrade
|
| Stock-Based Compensation | 6.07 | 3.66 | 4.75 | 5.74 | 6.2 | Upgrade
|
| Provision & Write-off of Bad Debts | -1.22 | -1.26 | 0.96 | 0.06 | 0.05 | Upgrade
|
| Other Operating Activities | -1.22 | -3.44 | 0.08 | 0.07 | 0.11 | Upgrade
|
| Change in Accounts Receivable | -0.76 | -1.28 | 2.26 | -3.32 | -2.58 | Upgrade
|
| Change in Inventory | -11.64 | 5.33 | 0.15 | -1.08 | -1.92 | Upgrade
|
| Change in Accounts Payable | 2.27 | -1.07 | 0.55 | -0.74 | 0.98 | Upgrade
|
| Change in Unearned Revenue | -0.12 | -0.32 | -0.61 | -0.4 | -0.21 | Upgrade
|
| Change in Other Net Operating Assets | 1.95 | 0.46 | 2.21 | -0.78 | -1.28 | Upgrade
|
| Operating Cash Flow | 13.5 | 12.11 | 7.12 | -15.1 | -24.16 | Upgrade
|
| Operating Cash Flow Growth | 11.52% | 70.14% | - | - | - | Upgrade
|
| Capital Expenditures | -0.29 | -0.16 | -0.15 | -0.33 | -0.41 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.02 | 0.01 | - | - | Upgrade
|
| Investing Cash Flow | -0.29 | -0.14 | -0.14 | -0.33 | -0.41 | Upgrade
|
| Long-Term Debt Repaid | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Net Debt Issued (Repaid) | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Issuance of Common Stock | 7.25 | 5.43 | - | 7.75 | 36.24 | Upgrade
|
| Repurchase of Common Stock | -0.25 | - | - | - | - | Upgrade
|
| Other Financing Activities | -0.07 | -0.05 | -0.08 | -0.08 | -0.11 | Upgrade
|
| Financing Cash Flow | 6.92 | 5.37 | -0.09 | 7.65 | 36.09 | Upgrade
|
| Net Cash Flow | 20.13 | 17.34 | 6.88 | -7.78 | 11.52 | Upgrade
|
| Free Cash Flow | 13.21 | 11.95 | 6.97 | -15.43 | -24.57 | Upgrade
|
| Free Cash Flow Growth | 10.60% | 71.42% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 10.21% | 11.99% | 8.34% | -21.42% | -36.43% | Upgrade
|
| Free Cash Flow Per Share | 0.15 | 0.15 | 0.09 | -0.22 | -0.37 | Upgrade
|
| Cash Interest Paid | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Levered Free Cash Flow | 4.88 | 9.61 | 9.47 | -9.64 | -13.5 | Upgrade
|
| Unlevered Free Cash Flow | 4.88 | 9.61 | 9.47 | -9.64 | -13.46 | Upgrade
|
| Change in Working Capital | -8.3 | 3.13 | 4.56 | -6.32 | -5.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.